In a major breakthrough for blood cancer patients, the U.S. FDA has granted accelerated approval to linvoseltamab-gcpt (brand name Lynozyfic, developed by Regeneron Pharmaceuticals) — a powerful new therapy for relapsed or refractory multiple myeloma (MM). This approval offers fresh hope for patients who have exhausted at least four previous treatment options.
🧪 What is Linvoseltamab?
Linvoseltamab is a bispecific antibody that acts like a precision-guided missile: it binds to BCMA (B-cell maturation antigen) on cancerous plasma cells and CD3 on immune T-cells, redirecting the body’s immune system to destroy the cancer.
It’s now the third BCMA-targeting bispecific antibody approved for multiple myeloma — and it’s showing strong clinical potential.
🎯 Who is it for?
Lynozyfic is approved for adult patients with multiple myeloma who have undergone at least four prior therapies, including:
- A proteasome inhibitor (PI)
- An immunomodulatory drug (IMiD)
- An anti-CD38 monoclonal antibody
🔬 What the Data Shows
The FDA based its approval on compelling results from the Phase 1/2 LINKER-MM1 trial:
- 70% Objective Response Rate (ORR)
- 45% Complete Response or better
- Responses began as early as 0.5 months after treatment
- Median Duration of Response (DOR): ~29 months
- Lower infection rates over time due to response-adapted dosing
🗣️ “Lynozyfic showed deep and durable responses in heavily pre-treated patients. Its flexible dosing reduces treatment burden — a real patient-centric advancement,” said Dr. Sundar Jagannath, trial investigator from Mount Sinai.
🧬 How is it given?
After an initial step-up dosing, Lynozyfic is administered weekly, with frequency reducing over time:
- Every 2 weeks after 16 weeks
- Every 4 weeks for patients with deep responses after 24 weeks
This “response-adapted” approach helps maintain remission while minimizing side effects.
⚠️ Safety First
Like other T-cell engaging therapies, Cytokine Release Syndrome (CRS) was observed in 46% of patients, but most cases were mild and resolved within hours.
🌍 Global Momentum
The European Medicines Agency approved linvoseltamab earlier in April 2025, making this a globally recognized treatment for patients with advanced myeloma.
💬 Why It Matters
Multiple myeloma remains a challenging cancer with high relapse rates, especially after standard treatments fail. With its innovative mechanism, strong clinical results, and more convenient dosing schedule, Lynozyfic brings a fresh wave of optimism to patients and clinicians alike.
“This is not just a new drug — it’s a new way to treat multiple myeloma.”
— BioPatrika Editorial Team
📚 Sources:
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
📢 Advertise with BioPatrika – Reach the Right Audience, Fast!
